Blair William & Co. IL Lowers Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Blair William & Co. IL cut its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 10.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,962 shares of the biopharmaceutical company's stock after selling 1,372 shares during the quarter. Blair William & Co. IL's holdings in Alnylam Pharmaceuticals were worth $2,815,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in ALNY. Sava Infond d.o.o. acquired a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at about $407,000. Elo Mutual Pension Insurance Co raised its position in Alnylam Pharmaceuticals by 18.3% during the 4th quarter. Elo Mutual Pension Insurance Co now owns 13,208 shares of the biopharmaceutical company's stock worth $3,108,000 after buying an additional 2,043 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in Alnylam Pharmaceuticals by 11.0% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 94,698 shares of the biopharmaceutical company's stock worth $22,186,000 after buying an additional 9,393 shares during the last quarter. Zions Bancorporation N.A. lifted its stake in Alnylam Pharmaceuticals by 13.5% during the 4th quarter. Zions Bancorporation N.A. now owns 672 shares of the biopharmaceutical company's stock valued at $158,000 after acquiring an additional 80 shares during the period. Finally, TD Asset Management Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 3.2% in the 4th quarter. TD Asset Management Inc. now owns 504,038 shares of the biopharmaceutical company's stock valued at $118,605,000 after acquiring an additional 15,755 shares during the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 1,213 shares of the business's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $309,521.21. Following the transaction, the chief executive officer now directly owns 81,526 shares in the company, valued at $20,802,989.42. The trade was a 1.47 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Phillip A. Sharp sold 11,250 shares of the stock in a transaction that occurred on Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total transaction of $3,093,750.00. The disclosure for this sale can be found here. Insiders sold 71,234 shares of company stock valued at $19,958,097 in the last three months. 1.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

ALNY has been the subject of a number of research reports. Needham & Company LLC restated a "buy" rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. Redburn Atlantic initiated coverage on Alnylam Pharmaceuticals in a report on Monday, March 31st. They issued a "buy" rating and a $353.00 price objective for the company. Stifel Nicolaus upped their target price on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a "buy" rating in a research note on Monday, March 31st. Sanford C. Bernstein reduced their price target on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating for the company in a research report on Tuesday, January 7th. Finally, JPMorgan Chase & Co. upgraded Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and upped their price objective for the stock from $280.00 to $328.00 in a research report on Monday, March 24th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $316.25.

Alnylam Pharmaceuticals Price Performance

NASDAQ ALNY traded down $26.42 during trading hours on Friday, hitting $235.74. 1,881,579 shares of the company's stock traded hands, compared to its average volume of 844,661. The company has a market capitalization of $30.67 billion, a PE ratio of -108.64 and a beta of 0.30. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39. The firm's 50-day moving average is $259.03 and its 200-day moving average is $260.23.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). Equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.